AnGes MG,Inc. AnGes MG,Inc. Japanese Site
News Releases
About Us
Projects
For Investors
What's New
Back Numbers
April 14, 2008 : AnGes MG, Inc. Launched Naglazyme in Japan
April 7, 2008 : Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis
March 28, 2008 : AnGes Submits NDA for HGF Gene Therapy
March 28, 2008 : AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme
February 25, 2008 : Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI
February 12, 2008 : Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis
February 8, 2008 : Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis
November 13, 2007 : AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe-
October 29, 2007 : Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan
August 31, 2007 : A Research-and-Development Project of GenomIdea Inc., a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector -
August 29, 2007 : Basic Patent of HGF Gene Therapy is Granted in Korea
August 13, 2007 : AnGes MG, Inc. Submits BLA for Naglazyme in Japan
July 11, 2007 : Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent)
   
Copyright 2004 AnGes MG All rights reserved. Contact | Site Map | Site Policy | Privacy Policy